✦ LIBER ✦

4518 POSTER First-line bevacizumab improves progression-free survival with lower doses of interferon-a2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN)

✍ Scribed by Melichar, B.; Koralewski, P.; Pluzanska, A.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Moore, N.; Escudier, B.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

4008 POSTER Bevacizumab/interferon-alpha

✍ S. Bracarda; P. Koralewski; A. Pluzanska; A. Ravaud; C. Szczylik; C. Chevreau; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 85 KB

7123 First-line bevacizumab + reduced-do

✍ Melichar, B.; Bracarda, S.; Bellmunt, J.; Ravaud, A.; Negrier, S.; Jethwa, S.; E 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

A multinational phase II trial of bevaci

✍ Melichar, B.; Bracarda, S.; Matveev, V.; Alekseev, B.; Ivanov, S.; Zyryanov, A.; 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 191 KB

1301 POSTER Assessment of Progression-fr

✍ S. Neqrier; A.G. Bushmakin; J.C. Cappelleri; C. Charbonneau; R. Sandin; M.D. Mic 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

94 A REAL-LIFE COMPARATIVE EFFECTIVENESS

✍ G.H. Mickisch; B. Schwander; B. Escudier; J. Bellmunt; J.P. Maroto; C. Porta; S. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Prediction of Progression-Free Survival

✍ Pierre I. Karakiewicz; Maxine Sun; Joaquin Bellmunt; Vesna Sneller; Bernard Escu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 546 KB